Viking Therapeutics (NASDAQ: VKTX) is set to give its latest quarterly earnings report on Wednesday, 2025-10-22. Here's what ...

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Viking Therapeutics (VKTX) is back in the spotlight with investors eyeing the company’s advancing clinical pipeline, including its VK2735 obesity drug now in phase 3 trials. Expectations are also ...

It has been a little more than two months since my last Viking Therapeutics, Inc. (NASDAQ:VKTX) article, where I highlighted their promising pipeline for obesity, NASH/MASH, and X-ALD programs that ...

Joining me now, Michele Schneider, Chief Strategist at MarketGauge. Michele, great to have you here at the desk. Michele ...

Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Explore the exciting world of Viking Holdings (NYSE: VIK) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...